Scalable Solutions Office: Office-Wide Innovative Solutions Opening for Advanced Research Projects Agency for Health

Active
Yes
Status
Posted
Published Date
March 14th, 2024
Close Date
March 14th, 2025
Expected No. Awards
100
Opportunity No.
ARPA-H-SOL-24-105

Agency

Advanced Research Projects Agency for Health (HHS-ARPAH)

Eligible Applicants

Small Businesses

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Other

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The federal grant notice titled "Scalable Solutions Office: Office-Wide Innovative Solutions Opening for Advanced Research Projects Agency for Health" is seeking solution summaries and proposals for projects that fall within the general scope of the ARPA-H Scalable Solutions mission office. The goal of this grant is to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise. The grant is specifically looking for projects that focus on rapid innovation, partnerships, flexible distribution networks, and streamlined manufacturing processes. The grant is open to small businesses and does not require cost sharing or matching. The deadline for submission is March 14, 2025, and it is expected that 100 awards will be given. For more information and to apply, please visit the following link: Additional Information.

Description

This ISO seeks solution summaries and proposals for projects that fall within the general scope of the ARPA-H Scalable Solutions mission office. SSO expands what is technically possible by developing approaches that will leverage an interdisciplinary approach and collaborative networks to address challenges of geography, distribution, manufacturing, data and information, thereby improving health care access and affordability. In the United States, many communities and remote areas lack access to timely and quality health care, which leads to disparities in health outcomes for those populations. Bottlenecks during the manufacturing processes of products and health technologies also lead to delays and limited availability, preventing effective distribution of health care solutions to areas of need, especially in emergencies.ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. The following SSO interest areas categorize the ground-breaking solutions we seek to support:Scalable Technologies and Interventions:• Approaches to improve affordability and equitable access to health care that are adaptable to various geographic, demographic, economic contexts and can be rapidly deployed at scale (e.g., drug-repurposing*, telemedicine, point-of-care diagnostics, and modular health care infrastructure).• Tailored solutions for the pediatric population that provide parity in access to treatments and other health care interventions with the adult population and adapt to the pediatric patient’s changing physiology and developmental status over the course of years.• Transformational approaches to reduce or eliminate health disparities, including tools and models for product design and care delivery that scale novel approaches in human factors and human-centered design to respond to full diversity of patients.• Tools to enable the scaling of provider and institutional capabilities (e.g., school nurses and schools, walk-in clinics, homesteading care) to address unmet health care access needs and expand availability of critical services.• Foundational capabilities to accelerate diagnoses and reduce the cost of treatments for rare diseases wherever patients are, without the need for specialized facilities or healthcare expertise.* Solution summaries and proposals that focus on testing drugs for effectiveness for other disease states or use cases, are unlikely to be funded unless including additional R&D, or providing gains in cost reduction, accessibility, and/or equity.Collaborative Distribution Networks:• Methods for standardization, automation, and democratization of complex procedures 5 including, but not limited to, histopathology, rare disease diagnosis and treatment, and surgical interventions to ensure access and delivery to populations diverse in demographics, geographies, and resources at scale.• Approaches to enhance delivery of effective healthcare solutions in rural or low resource settings, including but not limited to "last mile delivery”, at-home monitoring, imaging, drug delivery, telehealth augmentation, and support for remote medical procedures with limited need for specialized training.• Technologies to enable the deployment of critical healthcare resources rapidly, equitably, and securely at scale to the point of need in permissive and non-permissive (i.e., damaged infrastructure, cyber-denied) environments during a public health crisis or natural disaster.• Solutions to scale education and training of critical healthcare resources for health care providers and patients to ensure information integrity to prevent negative impacts to resource use/uptake.• Innovative information technology, data and analytic products and technologies to enable ordering, inventory management, situational awareness, allocation planning and demand forecasting of critical healthcare resources during a public health crisis or natural disaster.Biomanufacturing Innovations*:• Innovative manufacturing technologies and approaches that reduce cost, shorten the timeline for production, advance domestic competitiveness and reduce supply chain risk of biologics, cellular and gene therapies, pharmaceuticals, medical devices and personal protective equipment.• New approaches to support predictable, programable biological production of conventional and novel materials reliability at scale in a cost-effective sustainable manner.• Novel solutions to reduce the reliance on specialized handling and cold chain management of pharmaceuticals and biologics.• Scalable innovations to advance and strengthen biomanufacturing supply chain and resolve bottlenecks including:o Advances in production of active pharmaceutical ingredients, process consumables, and other critical materials (i.e., enzymes, cell lines, etc);o Novel biomanufacturing-related data products, technologies or models to integrate into supply chain situational awareness systems;o Alternative materials and new manufacturing capabilities for personal protective equipment; ando Improvement of capabilities sustainably re-shore manufacturing and utilize a broad array of readily accessible and cost-efficient feedstocks as part of strengthening the local and national industry base.• Analytics and novel sensor systems to precisely manage bioproduction, real-time release assays, and predictive capabilities to inform tuning of biological chassis for efficient and effective scale-up of manufacturing to industrial scale.*ARPA-H is not interested in approaches that merely increase capacity reservation.Other high-quality submissions that propose revolutionary technologies that meet the goals of SSO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

Contact Information

Attachments
49 KB
268 KB
48 KB
219 KB
272 KB
110 KB
468 KB
30 KB
129 KB
36 KB
424 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Health Science Futures: Office-Wide Innovative Solutions Opening for Advanced Research Projects Agency for Health
Advanced Research Projects Agency for Health
The Advanced Research Projects Agency for Health (ARPA-H) has posted a federal grant opportunity titled "Health Science Futures: Office-Wide Innovative Solutions Opening." This grant seeks solution summaries and proposals for projects that align with the ARPA-H Health Science Futures (HSF) mission office. HSF aims to overcome scientific and technological limitations in healthcare and support cutting-edge research programs with the potential for real-world impact. The grant is open to small businesses and does not require cost sharing or matching. It falls under the category of Science and Technology and other Research and Development. The opportunity is discretionary and has a CFDA number of 93.384. The deadline for submission is March 14, 2025. The grant is expected to result in 100 awards. The grant description provides detailed information on the specific interest areas that the funding seeks to support, including breakthrough technologies, transformative tools, and platform systems. These areas encompass a wide range of research and development projects aimed at improving health outcomes and addressing various diseases and conditions. Proposals should use innovative approaches to enable revolutionary advances in medicine and healthcare. While disease-agnostic approaches are encouraged, proposals addressing specific diseases such as cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease are also welcome. Proposals that represent incremental advances or are at the clinical trial stage are excluded. Additionally, proposals related to policy changes, traditional education and training, or physical infrastructure construction are outside the scope of the ARPA-H mission. For more information and to access the grant opportunity, interested parties can visit the following link: [Additional Information](https://sam.gov/opp/0f71794fda5b47b68ee28139c2468fdb/view). For any inquiries or assistance, the grantor contact is Mark Baxter, a Contract Specialist at ARPA-H. He can be reached at mark.baxter@arpa-h.gov or by phone at 3018274852.
Resilient Systems Office: Office-Wide Innovative Solutions Opening for Advanced Research Projects Agency for Health
Advanced Research Projects Agency for Health
The federal grant notice titled "Resilient Systems Office: Office-Wide Innovative Solutions Opening for Advanced Research Projects Agency for Health" is seeking solution summary and proposal submissions for projects that fall within the scope of the ARPA-H mission Resilient Systems Office (RSO). RSO's interest areas will address systemic challenges across the healthcare and public health landscape by investing in cutting-edge technologies that address long-standing gaps in the quality, efficacy, and consistent availability of care. The grant is open to small businesses and does not require cost sharing or matching. The funding instrument type is "Other" and the category of funding activity is "Science and Technology and other Research and Development". The opportunity is posted under the discretionary category and falls under CFDA number 93.384. The close date for submissions is March 14, 2025. The expected number of awards is 100. The grant description highlights the need for innovations that enhance the adaptability, reliability, and interoperability of the health ecosystem. The grant is particularly interested in innovations that foster flexibility and enable adaptation to system stressors, with the goal of delivering high-quality care and improving health outcomes. The grant seeks proposals in three interest areas: Sociotechnical System Innovation, Health Ecosystem Integration, and Adaptive & Antifragile Solutions. Proposals should use innovative approaches to enable revolutionary advances in science, technology, systems, or methodology. Proposals that represent an evolutionary or incremental advance in the state of the art or technology that has reached the clinical trial stage are excluded. The grant does not support proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure. For more information and to submit proposals, interested parties can visit the additional information URL provided.
Proactive Health Office: Office-Wide Innovative Solutions Opening for Advanced Research Projects Agency for Health
Advanced Research Projects Agency for Health
The Advanced Research Projects Agency for Health (ARPA-H) is seeking innovative solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. The Proactive Health Office (PHO) at ARPA-H is specifically interested in novel prevention, detection, and prophylactic treatment methods for disease, population-level approaches to increase the adoption of prevention and wellness behaviors, and system innovation for the delivery of proactive health outcomes. The goal is to develop methods and interventions that can be deployed at a population-scale to drastically improve the health of Americans throughout their lives. Small businesses are eligible to apply for this grant opportunity. For more information, please visit the [additional information link](https://sam.gov/opp/0f71794fda5b47b68ee28139c2468fdb/view).
Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT)
Advanced Research Projects Agency for Health
The Advanced Research Projects Agency for Health (ARPA-H) has posted a funding opportunity for the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) Program. This program aims to support the development of personalized regenerative immunocompetent nanotechnology tissue. ARPA-H anticipates multiple awards and award types resulting from this announcement. Interested parties are encouraged to review the attached PRINT Innovative Solutions Opening (ISO) ARPA-H-SOL-24-101. In addition, ARPA-H will be hosting a Proposer's Day on May 07, 2024, to facilitate teaming and enhance understanding of the PRINT Program. The event will allow for both in-person and virtual participation, with registration closing on April 30, 2024. Proposals for the solution summary are due on May 28, 2024, and will be by invitation only. The proposal due date is July 8, 2024. For more information about ARPA-H and this funding opportunity, please visit the provided link.